Zypher Lifesciences Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Zypher Lifesciences Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $450.0K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Zypher Lifesciences Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $450.0K Trade | TransData Nexus

Zypher Lifesciences Private Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $450.0K Total Trade · DGFT Verified

Zypher Lifesciences Private Limited is an Indian pharmaceutical exporter with a total trade value of $450.0K across 3 products in 3 therapeutic categories. Based on 9 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Levofloxacin ($150.0K), Ofloxacin ($150.0K), Sitagliptin ($150.0K).

Zypher Lifesciences Private Limited — Export Portfolio & Destination Treemap

Zypher Lifesciences Private Limited pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Zypher Lifesciences Private Limited? — Company Overview & Market Position

Zypher Lifesciences Private Limited, established on March 19, 2007, is a privately held pharmaceutical company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U29297DL2007PTC160681. Initially incorporated with an authorized and paid-up capital of ₹100,000, Zypher Lifesciences has since expanded its operations and capital base.

The company's registered office is located at Unit No 308-309, Jaksons Crown Heights, Plot No 381, Twin District Centre, Sector-10, Rohini, New Delhi, Delhi, 110085, India. Zypher Lifesciences specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to various therapeutic categories. The company has demonstrated a consistent growth trajectory, with a reported compound annual growth rate (CAGR) of 20%, reflecting its expanding product portfolio and market presence.

What Does Zypher Lifesciences Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Levofloxacin$150.0K 2

Product Portfolio — Top 3 by Export Value

Zypher Lifesciences Private Limited exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Levofloxacin	Antibiotics	$150.0K	3	0.2%	4
2	Ofloxacin	Advanced Antibiotics	$150.0K	3	0.1%	14
3	Sitagliptin	Diabetes & Endocrine	$150.0K	3	0.2%	6

Zypher Lifesciences Private Limited exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $450.0K. The top category is Antibiotics (33.3% of portfolio), followed by Advanced Antibiotics (33.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Zypher Lifesciences Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Zypher Lifesciences operates state-of-the-art manufacturing facilities in India, designed to meet stringent regulatory standards. The facilities are equipped with advanced machinery and instruments, ensuring compliance with Good Manufacturing Practices (GMP) and other international quality standards. These plants are accredited by the Italian Medicines Agency (AIFA) for manufacturing commercial drug products for the European Union market, and also hold approvals from the Ministry of Health of the Republic of Turkey.

3Key Leadership

The leadership team at Zypher Lifesciences comprises directors Aditya Bhatia, Gunjan Bhatia, and Anita Bhatia. Aditya Bhatia serves as a director, with Gunjan Bhatia and Anita Bhatia also holding directorial positions. The company's strategic direction and growth initiatives are guided by this experienced leadership team, focusing on expanding product offerings and enhancing global market presence.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Zypher Lifesciences Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Zypher Lifesciences has established a presence in several regulated markets, including the European Union (EU) and Turkey. The company's manufacturing facilities are approved by the Italian Medicines Agency (AIFA), allowing it to supply commercial drug products to the EU market. Additionally, the facilities have received approval from the Ministry of Health of the Republic of Turkey, facilitating market access in Turkey. These regulatory approvals underscore the company's commitment to adhering to international quality standards and expanding its footprint in regulated markets.

2Emerging Markets

Zypher Lifesciences has extended its reach into emerging markets across Asia, Africa, the Commonwealth of Independent States (CIS), the Middle East and North Africa (MENA) region, Russia, and Latin America. The company's marketing strategy in these regions focuses on enhancing visibility and connecting with customers and business associates. While specific details regarding WHO prequalification are not available, the company's adherence to international quality standards positions it favorably for market penetration in these regions.

3Geographic Strategy

Zypher Lifesciences Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Zypher Lifesciences' interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly available. The company's current focus appears to be on markets with established regulatory approvals, such as the EU and Turkey.

2WHO & EU GMP

Zypher Lifesciences' manufacturing facilities are accredited by the Italian Medicines Agency (AIFA) for compliance with EU Good Manufacturing Practice (GMP) standards. This accreditation allows the company to manufacture and supply pharmaceutical products to the EU market. Additionally, the facilities have received approval from the Ministry of Health of the Republic of Turkey, indicating adherence to international quality standards.

3CDSCO & Indian Regulatory

Specific details regarding Zypher Lifesciences' compliance with the Central Drugs Standard Control Organisation (CDSCO) and other Indian regulatory bodies, including manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs), are not publicly available. The company's adherence to international quality standards suggests compliance with domestic regulatory requirements.

Zypher Lifesciences Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Zypher Lifesciences operates in a competitive pharmaceutical industry, with numerous companies offering similar products across various therapeutic categories. While specific market share data is not available, the company's focus on niche formulations in hormones and oncology, along with its international accreditations, positions it as a specialized player in these segments. The company's expansion into emerging markets further enhances its competitive positioning.

2Key Differentiators

Zypher Lifesciences' key differentiators include its specialization in niche formulations, particularly in hormones and oncology, and its adherence to international quality standards, as evidenced by certifications from AIFA and the Ministry of Health of the Republic of Turkey. The company's commitment to Quality by Design (QbD) principles ensures that quality is integrated into the product development process, leading to high-quality pharmaceutical products.

3Strategic Position

Zypher Lifesciences is strategically positioned as a manufacturer of generic pharmaceutical formulations, with a focus on niche segments such as hormones and oncology. The company's adherence to international quality standards and its expansion into both regulated and emerging markets reflect a strategic direction aimed at sustainable growth and global market presence. Future outlooks suggest continued emphasis on product diversification and market expansion.

Buyer Due Diligence Brief — Evaluating Zypher Lifesciences Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Zypher Lifesciences has demonstrated a consistent track record in pharmaceutical manufacturing, with a reported compound annual growth rate (CAGR) of 20%, indicating reliable export volume and consistency. The company's adherence to international quality standards, as evidenced by certifications from AIFA and the Ministry of Health of the Republic of Turkey, underscores its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Zypher Lifesciences as a supplier:

WHO-GMP Certification: To ensure compliance with World Health Organization Good Manufacturing Practices.

EU GMP Certification: To confirm adherence to European Union Good Manufacturing Practices.

ISO Certifications: To assess the company's quality management systems.

These certifications can typically be verified through the company's official website or by contacting the relevant regulatory bodies.

Frequently Asked Questions — Zypher Lifesciences Private Limited

How many pharmaceutical products does Zypher Lifesciences Private Limited export from India?

Zypher Lifesciences Private Limited exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Levofloxacin ($150.0K), Ofloxacin ($150.0K), Sitagliptin ($150.0K). Total export value is $450.0K.

What is Zypher Lifesciences Private Limited's total pharmaceutical export value?

Zypher Lifesciences Private Limited's total pharmaceutical export value is $450.0K, based on 9 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Zypher Lifesciences Private Limited cover?

Zypher Lifesciences Private Limited exports across 3 therapeutic categories. The largest are Antibiotics (33.3%, 1 products), Advanced Antibiotics (33.3%, 1 products), Diabetes & Endocrine (33.3%, 1 products).

Get Full Zypher Lifesciences Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.